SMS Pharma Tightens Grip on Peptides Arm with ₹30 Mn Strategic Buyout

In a decisive move to consolidate its biotech footprint, SMS Pharmaceuticals Ltd. has increased its stake in SMS Peptides Pvt. Ltd. to a commanding 99.98%, acquiring additional shares for ₹30 million. This strategic acquisition underscores SMS Pharma’s commitment to strengthening its presence in the high-growth peptide therapeutics segment.

 

The transaction, executed through a structured internal transfer, reflects the company’s long-term vision of integrating vertically across the pharmaceutical value chain. SMS Peptides, a specialized subsidiary focused on complex peptide synthesis and high-purity APIs, plays a critical role in SMS Pharma’s innovation pipeline.

 

The ₹30 million acquisition cost is seen as a calculated investment to unlock synergies in R&D, manufacturing scalability, and regulatory compliance, especially as global demand for peptide-based drugs surges. The move also aligns with SMS Pharma’s broader strategy of expanding its specialty API portfolio and enhancing shareholder value through focused capital deployment.

 

Key Highlights:

 

₹30 million spent to raise stake in SMS Peptides to 99.98%

Strengthens position in peptide-based APIs and complex molecules

Enhances vertical integration and innovation capabilities

Supports global expansion in regulated markets

Reinforces SMS Pharma’s growth trajectory in niche pharma segments

 

With this near-total ownership, SMS Pharmaceuticals is poised to accelerate product development and deepen its competitive edge in the global pharmaceutical landscape.

 

Sources: SMS Pharmaceuticals Ltd Corporate Filing, BSE Announcement, Financial Express Market Update